- Home
- ADN vs BLRX Comparison
ADN vs BLRX Comparison
Compare ADN & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADN
- BLRX
- Stock Information
- Founded
- ADN 2006
- BLRX 2003
- Country
- ADN United States
- BLRX Israel
- Employees
- ADN N/A
- BLRX N/A
- Industry
- ADN Power Generation
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- ADN Utilities
- BLRX Health Care
- Exchange
- ADN Nasdaq
- BLRX Nasdaq
- Market Cap
- ADN 11.3M
- BLRX 12.2M
- IPO Year
- ADN N/A
- BLRX 2011
- Fundamental
- Price
- ADN $3.02
- BLRX $2.75
- Analyst Decision
- ADN
- BLRX Buy
- Analyst Count
- ADN 0
- BLRX 2
- Target Price
- ADN N/A
- BLRX $26.00
- AVG Volume (30 Days)
- ADN 18.0K
- BLRX 26.6K
- Earning Date
- ADN 12-27-2024
- BLRX 05-27-2025
- Dividend Yield
- ADN N/A
- BLRX N/A
- EPS Growth
- ADN N/A
- BLRX N/A
- EPS
- ADN N/A
- BLRX N/A
- Revenue
- ADN $8,157,000.00
- BLRX $28,940,000.00
- Revenue This Year
- ADN $2,232.99
- BLRX N/A
- Revenue Next Year
- ADN $91.56
- BLRX N/A
- P/E Ratio
- ADN N/A
- BLRX N/A
- Revenue Growth
- ADN 274.35
- BLRX 502.92
- 52 Week Low
- ADN $1.71
- BLRX $2.85
- 52 Week High
- ADN $8.79
- BLRX $35.60
- Technical
- Relative Strength Index (RSI)
- ADN 28.28
- BLRX 35.52
- Support Level
- ADN $3.05
- BLRX $3.01
- Resistance Level
- ADN $4.82
- BLRX $3.61
- Average True Range (ATR)
- ADN 0.43
- BLRX 0.20
- MACD
- ADN -0.20
- BLRX 0.00
- Stochastic Oscillator
- ADN 4.17
- BLRX 0.00
About ADN Advent Technologies Holdings Inc.
Advent Technologies Holdings Inc is an innovation-driven company in the fuel cell and hydrogen technology space. The company develops, manufactures, and assembles complete fuel cell systems and the critical components that determine the performance of hydrogen fuel cells and other energy systems. It serves automotive; aviation and power generation industries. It generates revenue from the sale of fuel cell systems and the sale of MEAs, membranes, and electrodes for specific applications in the fuel cell and energy storage (flow battery) markets.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.